Evgen Pharma Share Discussion Threads

[pdt] 12/9/2019 22:06

Blakeysangel - thanks for keeping us informed and hopefully SFX-01 will keep working for you for a long time to come. Enjoy the seaside, incidently I live on the coast looking out over water and love it.

[blakeysangel] 12/9/2019 21:33

Thanks everyone for your support. It’s interesting ,PDT ,that the next trial is at a earlier stage, 2nd line treatment after CDK4/6, I’m yet to have a CDK4/6 as I’m on tamoxifen so perhaps if things do progress I maybe able to drop on a trial again with STEM in partnership with a different treatment. PDT I’ve been on the trial since early June 2018 and won’t be scanned again till November at the earliest.Till then the seaside and enjoying early retirement is what I’ll be doing 😀😀.

[pdt] 12/9/2019 14:17

diamondstar1 - in these cases they are trying to increase rather than inhibit NRF2. SFX-01 is sulforaphane based and one of the unique properties is that it crosses the blood brain barrier and being in the SFX-01 formulation it is stable and suitable for clinical studies. There were some studies into the analogues and SFX-01 was the most potent NRF2 activator for use in SAH.

There are other companies with NRF2 activators such as Reata Pharma (US) and C4X (UK) has an early stage molecule.

There are some links on Evgen's website re action of SFX-01 and Multiple Sclerosis.

[diamondstar1] 12/9/2019 13:06

Thanks PDT - you are perfectly right. There was an announcement on 28-Aug-2019, that the last patient had achieved final study visit. Add 6 weeks to this - and the results could be released as early as mid October, or possibly late Oct as you suggest.

PDT - do you understand the key differences between NRF2 inhibition with SFX-01 and other NRF2 inhibitors e.g. Biogen’s marketed product for relapsing-remitting multiple sclerosis?

[pdt] 12/9/2019 12:50

diamondstar1 - the company announced that the last data was collected end of August and that results would be Q4. I suspect end of October.

A good article worth a read is;

Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential

[diamondstar1] 12/9/2019 12:31

Hi there, I’m totally new to this Evgen blog. Have not invested as yet, but I am potentially interested.
Firstly, the question I’m asking is when the results of the Ph2 trial will be released? Quick check on clinicaltrials.gov shows that the study sites are active, but have stopped recruiting. Thus, the study has completed recruiting the last patient in early Sept as my guess. Since the patients are dosed on SFX-01 300mg twice daily for 4 weeks, and followed up for Primary Endpoints for a total of 4 weeks, the estimated study completion date should be end-Sept, or perhaps early October. Once study is completed, there will be intensive activity in collecting all relevant clinical trial data, quality checking the data, and producing tables and listings. This activity towards database lock usually takes 4-6 weeks and should span across the whole of October, possibly the first half of November.

Hence, my target date for disclosure of the Ph2 SAH results would be mid November. It looks to me like we are about 2 months away from finding out the Ph2 results. Interesting times ahead!

[snowyflake] 12/9/2019 10:46

Blakeysangel - setting aside one's commercial hopes for SFX-01, I and am I sure others wish you all the very best.

[pdt] 12/9/2019 10:25

Blakeysangel - it is great to hear your news!

It is also encouraging for the prospects of the next trial. To be viewed as a success they are looking for about 8 months of PFS. I think Blakeysangel must be on about 15 months and when the trial results were announced there was someone on 14 months. And some 13 people on the compassionate use programme of 6 months plus duration.

I believe the company hopes for even better results overall from the new trial since it will be positioned, at an earlier stage, as a second line treatment after CDK4/6.

Combined with excellent safety and low side effects I would have thought that a partner may be interested in this next trial.

More information should be disclosed at the Barcelona event at the end of this month. Exciting times for Evgen especially with the SAH results also due in Q4.

[nobbygnome] 11/9/2019 15:52

Your positive attitude is infectious!

[blakeysangel] 11/9/2019 15:15

Hi Nobby,
Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀

[blakeysangel] 11/9/2019 15:01

Hi Nobby,
Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀

[nobbygnome] 11/9/2019 13:46

Good news!

Do you have any discernible side effects from SFX01?

[blakeysangel] 11/9/2019 13:42

Hi,
Onco appointment done today and continuing on Stem SFX01 for at least another 2 months till next scan... feeling happy!! Just need the Share price rise! 😀😀😀

[snowyflake] 06/9/2019 19:35

I am a new shareholder as of yesterday and have read the latest year's accounts. The last two placings have each been at higher prices - somewhat unusual one may think - that shows confidence in the company and what the directors are trying to achieve on the part of the placees.

The directors say that the company, on current estimates, is funded until after 2020; note after 2020. Like solicitors and other professionals, not all doctors are honest but I personally rate these directors.

The SFX-01 clinical trial results should be released in Q4 2019- i.e. anytime from and including this October until the end of December but I guess pre- Christmas as the backstop (that hateful word!!).

Also, the directors, unlike those of so many junior companies, are not taking inordinate salaries and treating the company as their thiefdom - so often causing a company to be attacked by the rogue bloggers and thus destroying share value.

The stock could have an upward move soon.

[shares188] 06/9/2019 19:19

Due a move upwards

[lovewinshatelosses] 05/9/2019 10:09

I agree - clearly very interesting news and fascinating too. I am looking forward to seeing where this ends up in the years ahead.

[snowyflake] 05/9/2019 09:26

Today's news release is impressive. SFX-01 could prove of use beyond assisting autistic youngsters - say MS and other neurological problems.

[nobbygnome] 29/8/2019 06:58

It was a nothing RNS. So the last patient last visit happened; I am not sure that is worth RNSing. I guess we know that patient at least survived through to the end, although of course mortality is not a primary end point!

[90005nelson] 28/8/2019 23:31

Even better for us then. Nimodipine was the last approved drug for SAH 30yrs ago, with making just marginal improvement to patients. Any significant improvement for patients using SFX-01 will be transformational.

[babbler] 28/8/2019 23:17

there are other results due..Sept.

[90005nelson] 28/8/2019 21:38

Too much emphasis on the sellers, when it's the first piece of liquidity since the last placing. Timeline is early October around six weeks away, which is a long time on AIM but that gives plenty of opportunities to add to one's position, if wanted. As we get nearer to the results the share price will rise in anticipation.

[lovewinshatelosses] 28/8/2019 19:54

I agree - the RNS was not full of any great drama or fanfare (nor should they be IMO), but I am struggling to see what justified any drop at all to be honest. AIM is a funny old place. I might be tempted to have another small top up if this drops back to circa 15p, but the wiser decision might just be to sit tight and await full results...

[zed2002] 28/8/2019 16:39

which part were they not impressed with?

[buywell3] 28/8/2019 15:41

Market has not been very impressed with the RNS IMO

[babbler] 28/8/2019 14:39

Bloody crazy drop due to impatience.